Progression-free survival between the TACE + lenvatinib/pembrolizumab group and the TACE + dual placebos group (months) (IMAGE)

Kindai University

Progression-free survival between the TACE + lenvatinib/pembrolizumab group and the TACE + dual placebos group (months)

Caption

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer. ECOG=Eastern Cooperative Oncology Group. HBV=hepatitis B virus. HCV=hepatitis C virus. RECIST=Response Evaluation Criteria in Solid Tumours. *One-sided p value re-randomisation test; threshold p=0·025. †Scores are the sum of the number of tumours and largest tumour diameter in cm.

Credit

Prof. Masatoshi Kudo MD from Kindai University

Usage Restrictions

Must credit Kindai University

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.